<SEC-DOCUMENT>0001171843-26-004747.txt : 20260717
<SEC-HEADER>0001171843-26-004747.hdr.sgml : 20260717
<ACCEPTANCE-DATETIME>20260717073106
ACCESSION NUMBER:		0001171843-26-004747
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260717
FILED AS OF DATE:		20260717
DATE AS OF CHANGE:		20260717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evaxion A/S
		CENTRAL INDEX KEY:			0001828253
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39950
		FILM NUMBER:		261181859

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		PROVINCE COUNTRY:   	G7
		BUSINESS PHONE:		4552656554

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		PROVINCE COUNTRY:   	G7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Evaxion Biotech A/S
		DATE OF NAME CHANGE:	20201014
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_071726.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong></strong><strong>For the month of July 2026</strong></p><p style="text-align: center;">Commission File Number: <strong>001-39950</strong></p><p style="text-align: center;"><font><font style="font-size: 12pt;"><strong>Evaxion A/S</strong></font></font><br />(Exact Name of Registrant as Specified in Its Charter)</p><p style="text-align: center;"><strong>Dr. Neergaards Vej 5f<br />DK-2970&#160;Hoersholm<br />Denmark</strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p><p style="text-align: center;">Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]</p><p><!--<p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <u></u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <u></u></p><p><strong>Note:&#160;</strong>Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.&#160;</p>--></p><hr style="break-after: page;" noshade="noshade" /><p style="text-align: center;"><strong>INCORPORATION BY REFERENCE</strong></p><p>This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S&#8217;s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</p><p><font><p style="margin-left: 0px; margin-right: 0px; text-align: left;"><strong><font>Press Release</font></strong></p><p style="margin-left: 0px; margin-right: 0px; text-align: left;">On July 17, 2026, Evaxion A/S (the &#8220;Company&#8221;), a clinical-stage TechBio company specializing in developing AI-Immunology&#8482; powered vaccines, issued a press release titled "Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.</p><p style="text-align: left;"><font style="font-size: 10pt;"><strong>Exhibits</strong></font></p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Exhibit Number</strong></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Description</strong></font></td></tr><tr><td>&#160;</td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;">&#160;</font></td></tr><tr><td><a href="exh_991.htm"><font style="font-size: 10pt;">99.1</font></a></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><a href="exh_991.htm"><font style="font-size: 10pt;">Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026 </font></a></td></tr></table><p style="margin-left: 0px; margin-right: 0px; text-align: left;">&#160;</p></font></p><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-decoration: underline; text-align: left;" align="center" width="47%"><strong>Evaxion A/S</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: July 17, 2026</td><td width="6%">&#160;</td><td width="6%">By:</td><td style="text-decoration: underline; text-align: left;" align="center" width="47%">/s/ Helen Tayton-Martin&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">Helen Tayton-Martin</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%">Chief Executive Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td width="6%">&#160;</td><td style="text-align: left;" align="center" width="47%"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><strong>Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026</strong></p><p style="text-align: center;"></p><p>
 <ul><li style="text-align:justify;"><b>Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response</b></li><li style="text-align:justify;"><b>Data will also offer insight into the vaccine&#8217;s effect also as stand-alone treatment of patients with advanced melanoma</b></li><li style="text-align:justify;"><b>Unprecedented two-year data from the trial presented last year showed</b> <b>high response rates and an impressive durability of responses </b><br ><br ></li></ul>  <p align="justify">COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (&#8220;Evaxion&#8221;), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology&#153; platform, will present three-year clinical efficacy data from its phase 2 trial with personalized cancer vaccine candidate EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2026 to be held in Madrid, Spain, from October 23-27, 2026.</p>  <p align="justify">The data stems from a one-year extension of the phase 2 trial evaluating EVX-01 in patients with advanced melanoma (skin cancer). In the third year, patients received EVX-01 as stand-alone therapy, meaning the data will offer insight into the vaccine&#8217;s effect also when not administered in combination with anti-PD-1 therapy. Further, the data may also provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response.</p>  <p align="justify">&#8220;We are looking forward to presenting the data on EVX-01 at the important ESMO Congress. This will be an excellent opportunity for us to also discuss the data with stakeholders and potential business partners at a time when pivotal late-stage clinical data are continuing to emerge across the personalized cancer vaccine field,&#8221; says Birgitte R&#248;n&#248;, CSO &amp; COO of Evaxion.</p>  <p align="justify"><b>Convincing results</b><br >The three-year data will add to already convincing results from the phase 2 trial. The two-year data demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Additionally, a durable clinical benefit was observed as 92% of patients were still responding at two years follow-up and no relapses were observed.</p>  <p align="justify">54% of patients had a deepened response during treatment, improving from stable disease or partial response to partial or complete response. Tumor reduction (target lesions) was observed in 15 out of the 16 patients enrolled in the trial.</p>  <p align="justify">In the trial, EVX-01 induced an immune response in all patients, with 86% of the targeted neoantigens generating potent specific T-cell responses.</p>  <p align="justify">The phase 2 trial investigated EVX-01 in patients with advanced melanoma. Each patient enrolled in the trial received a unique vaccine designed and manufactured based on their individual biology. In the first two-years, patients received EVX-01 in combination with MSD&#8217;s (Merck &amp; Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA&#174; (pembrolizumab). In the third year, a subset of patients received EVX-01 as stand-alone therapy. KEYTRUDA&#174; is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA.</p>  <p align="justify"><b>Presentation details</b><br >Abstract title: EVX-01, a personalized cancer vaccine, induces sustained T-cell responses and durable disease control in advanced melanoma after three-year of follow-up<br >Presentation#: 2006P<br >Location: Poster Area &#8211; Hall 5<br >Topic: Investigational immunotherapy<br >Date/Time: October 24, 2026, at 12:00 - 12:45 CET<br >Presenter: Dr. Muhammad Adnan Khattak, Director, Oncology, One Clinical Research, Hollywood Private Hospital &amp; Edith Cowan University, Perth, WA, Australia</p>  <p align="justify"><b>About EVX-01</b><br >EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers. It is Evaxion&#8217;s lead clinical asset.</p>  <p align="justify">Designed with our AI-Immunology&#153; platform, EVX-01 and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient's immune system to fight off cancer by mounting a targeted response against tumors.</p>  <p align="justify"><b>About melanoma</b><br >Melanoma accounted for approximately 1 in 5 of the 1.5 million new skin cancer cases estimated globally in 2020 with approximately 325,000 cases and 57,000 deaths. The global burden from melanoma is estimated to increase to 510,000 new cases and 96,000 deaths by 2040 (Arnold et al., JAMA Dermatology 2022). The global market for melanoma treatments is estimated to grow to $7.4 billion by 2029 (GlobalData).</p>  <p align="justify"><b>Contact information</b>&#160;<br >Evaxion A/S<br >Mads Kronborg<br >Vice President, Investor Relations &amp; Communication<br >+45 53 54 82 96 <br >mak@evaxion.ai</p>  <p align="justify"><b>About Evaxion</b> <br >Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology&#153;. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.</p>  <p align="justify">With AI-Immunology&#153; we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.</p>  <p align="justify">We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients&#8217; lives by providing innovative and targeted treatment options.</p>  <p align="justify">For more information about Evaxion, AI-Immunology&#153; and our pipeline, please visit our website.&#160;</p>  <p align="justify"><b>Forward-looking statement</b>&#160;<br >This&#160;announcement contains forward-looking statements&#160;within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.&#160;The words&#160;&#8220;target,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;hope,&#8221; &#8220;aim,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;anticipate,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;can have,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; and other words and terms of similar meaning&#160;identify forward-looking statements.&#160;Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,&#160;the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our&#160;business from other significant geopolitical and macro-economic events;&#160;and other uncertainties affecting our business operations and financial condition.&#160;For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F&#160;and other filings&#160;with the US Securities and Exchange Commission (SEC), which are available at&#160;<b>www.sec.gov</b>.&#160;We do not assume any obligation to update any forward-looking statements except as required by law.&#160;</p> <p></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
